Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Conditions
Keywords
accelerated phase chronic myelogenous leukemia, adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia in remission, adult AML with 11q23 (MLL) abnormalities, blastic phase chronic myelogenous leukemia, chronic myelomonocytic leukemia, chronic phase chronic myelogenous leukemia, prolymphocytic leukemia, recurrent adult T-cell leukemia/lymphoma, refractory chronic lymphocytic leukemia, relapsing chronic myelogenous leukemia, secondary acute myeloid leukemia, stage I adult T-cell leukemia/lymphoma, stage I chronic lymphocytic leukemia, stage II adult T-cell leukemia/lymphoma, stage II chronic lymphocytic leukemia, stage III adult T-cell leukemia/lymphoma, stage III chronic lymphocytic leukemia, stage IV adult T-cell leukemia/lymphoma, stage IV chronic lymphocytic leukemia, recurrent adult Hodgkin lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, cutaneous B-cell non-Hodgkin lymphoma, recurrent cutaneous T-cell NHL, stage I cutaneous T-cell NHL, stage II cutaneous T-cell NHL, stage III cutaneous T-cell NHL, stage IV cutaneous T-cell NHL, extranodal marginal zone B-cell lymphoma of mucosal tissue, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma, contiguous st II adult diffuse large cell lymphoma, contiguous st II adult diffuse mixed cell lymphoma, contiguous st II adult diffuse sm cleaved cell lymphoma, contiguous st II grade 1 follicular lymphoma, contiguous st II grade 2 follicular lymphoma, contiguous st II grade 3 follicular lymphoma, contiguous st II mantle cell lymphoma, contiguous st II marginal zone lymphoma, contiguous st II small lymphocytic lymphoma, stage I adult diffuse large cell lymphoma, stage I adult diffuse mixed cell lymphoma, stage I adult diffuse small cleaved cell lymphoma, stage I grade 1 follicular lymphoma, stage I grade 2 follicular lymphoma, stage I grade 3 follicular lymphoma, stage I mantle cell lymphoma, stage I marginal zone lymphoma, stage I small lymphocytic lymphoma, noncontiguous st II adult diffuse large cell lymphoma, noncontiguous st II adult diffuse mixed cell lymphoma, noncontiguous st II adult diffuse sm cleaved cell lymphoma, noncontiguous st II grade 1 follicular lymphoma, noncontiguous st II grade 2 follicular lymphoma, noncontiguous st II grade 3 follicular lymphoma, noncontiguous st II mantle cell lymphoma, noncontiguous st II marginal zone lymphoma, noncontiguous st II small lymphocytic lymphoma, stage III adult diffuse large cell lymphoma, stage III adult diffuse mixed cell lymphoma, stage III adult diffuse small cleaved cell lymphoma, stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage III mantle cell lymphoma, stage III marginal zone lymphoma, stage III small lymphocytic lymphoma, stage IV adult diffuse large cell lymphoma, stage IV adult diffuse mixed cell lymphoma, stage IV adult diffuse small cleaved cell lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma, stage IV mantle cell lymphoma, stage IV marginal zone lymphoma, stage IV small lymphocytic lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult gr III lymphomatoid granulomatosis, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, de novo MDS, previously treated MDS, secondary myelodysplastic syndromes, Waldenstrom macroglobulinemia, myelodysplastic/myeloproliferative disease
Brief summary
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a monoclonal antibody, such as alemtuzumab, before transplant and tacrolimus and methotrexate after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects of donor stem cell transplant and to see how well it works in treating patients with high-risk hematologic cancer.
Detailed description
OBJECTIVES: * To evaluate the safety and toxicity of a reduced-intensity conditioning regimen followed by allogeneic bone marrow or peripheral blood stem cell transplantation from an HLA-matched unrelated donor in patients with high-risk hematologic malignancies. * To evaluate engraftment by peripheral blood chimerism analysis. * To determine the incidence and severity of acute and chronic graft-versus-host disease following the transplant. * To examine the possibility of controlling hematologic malignancies by induction of a graft-versus-leukemia/tumor effect. * To determine the disease-free survival, relapse, transplant-related mortality, and death from all causes. OUTLINE: * Reduced-intensity conditioning regimen: Patients receive 1 of 2 conditioning regimens according to diagnosis. * Regimen 1 (acute leukemia, myelodysplastic syndromes, myeloproliferative syndrome, or chronic myelogenous leukemia): Patients receive fludarabine phosphate IV over 30 minutes and busulfan IV over 3 hours on days -6 to -3 or orally 4 times daily on days -7 to -3. * Regimen 2 (lymphoproliferative malignancies): Patients receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 1 hour on days -5 to -3. Patients with CD20+ malignancies also receive rituximab IV over 4-6 hours on days -13, -6, 1, and 8. * Transplantation: Patients undergo allogeneic bone marrow or peripheral blood stem cell transplantation on day 0. * Graft-versus-host disease (GVHD) prophylaxis: Patients receive low-dose alemtuzumab subcutaneously on days -11 to -9 and tacrolimus IV over 24 hours beginning on day -3 and then orally twice daily beginning on day 14 and continuing until day 60, followed by a taper until day 180 in the absence of clinically significant GVHD. Patients also receive methotrexate on days 1, 3, and 6. Patients who exhibit persistent mixed chimerism or disease relapse/progression despite full withdrawal of immunosuppression may receive up to 3 donor lymphocyte infusions. Blood samples are taken on days 30, 60, and 100 and then every 4 weeks thereafter for chimerism studies by PCR analysis. After completion of study therapy, patients are followed periodically for up to 60 months.
Interventions
DRUGmethotrexate
5 mg/m2 administered on days +1, +3 and +6
BIOLOGICALalemtuzumab
43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)
BIOLOGICALgraft-versus-tumor induction therapy
curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL
BIOLOGICALrituximab
in patients with Cd20+ malignancies: rituximab 375 mg/m\*2 day -13. rituximab 1000 mg/m\*2 on days, -6, +1, +8.
DRUGbusulfan
For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
DRUGcyclophosphamide
750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
DRUGfludarabine phosphate
For patients with CLL, NHL & HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.
DRUGtacrolimus
0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO
PROCEDUREallogeneic bone marrow transplantation
Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
Sponsors
Blood and Marrow Transplant Group of Georgia
Northside Hospital, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 72 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of one of the following hematological malignancies: * CML, with 1 of the following: * In first CP AND failed imatinib mesylate therapy, defined as failure to obtain a hematologic remission at 3 months or a major cytogenetic response (i.e., Ph+ cells \< 35%) at 6 months or demonstrated clonal evolution or disease progression during therapy * In accelerated phase with \< 15% blasts * In blast crisis that has entered into a second CP following induction chemotherapy * AML, with 1 of the following: * In second or subsequent complete remission (CR) (i.e., \< 5% blasts by morphology, no residual leukemia by flow cytometry, and absence of cytogenetic abnormalities) * Failed primary induction chemotherapy, but subsequently entered into a CR with ≤ 2 subsequent re-induction chemotherapy treatment(s) * In first CR with intermediate-risk or poor-risk cytogenetics * ALL with 1 of the following: * In second or subsequent CR * In first CR AND presence of t(9;22) * MDS, with the following: * High-risk disease, defined by IPSS score of ≥ 1.5 at diagnosis AND meets 1 of the following criteria: * ≤ 10% blasts at diagnosis * In morphologic CR (\< 5% blasts) following cytoreductive chemotherapy * CMML, with 1 of the following: * ≤ 10% blasts at diagnosis * In morphologic CR (\< 5% blasts) following cytoreductive chemotherapy * CLL/PLL with the following: * Rai stage I-IV disease * Failed ≥ 1 prior chemotherapy regimen (including fludarabine phosphate) or ASCT * Documented chemosensitive or stable, non-bulky disease prior to transplant, defined as \< 20% bone marrow involvement AND lymph node size \< 3 cm in axial diameter * No bulky tumor masses, elevated lactate dehydrogenase (LDH), B symptoms, or progressive disease prior to transplant * Low-grade non-Hodgkin lymphoma (NHL) (i.e., small lymphocytic lymphoma, follicular center lymphoma \[grade 1 or 2\], marginal zone lymphoma, or B-cell lymphoma), with the following criteria: * Failed ≥ 1 prior chemotherapy regimen or ASCT * Documented chemosensitive or stable, non-bulky disease prior to transplant, defined as \< 20% bone marrow involvement AND lymph node size \< 3 cm in axial diameter * Received ≤ 3 prior chemotherapy regimens (monoclonal antibody therapy and involved-field radiotherapy are not considered a prior regimen) * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant * Mantle cell lymphoma, with the following: * Failed to achieve remission or recurred after either conventional chemotherapy or ASCT * Responsive or stable disease to most recent prior therapy * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant * Intermediate-grade NHL (i.e., follicular center lymphoma \[grade 3\] or diffuse large cell lymphoma), meeting the following criteria: * Failed to achieve remission or recurred after either conventional chemotherapy or ASCT * Documented chemosensitive, non-bulky disease prior to transplant, defined as at least a partial remission to salvage chemotherapy (≥ 50% reduction in diameter of all disease sites) * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant * Hodgkin lymphoma, with the following: * Relapsed after prior ASCT OR after ≥ 2 combination chemotherapy regimens and ineligible for ASCT * Documented chemosensitive, non-bulky disease prior to transplant, defined as at least a partial remission to salvage chemotherapy (≥ 50% reduction in diameter of all disease sites) * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant * Peripheral T-cell NHL, with the following: * Failed to achieve remission or recurred after either conventional chemotherapy or ASCT * Documented chemosensitive, non-bulky disease prior to transplant, defined as at least a partial remission to salvage chemotherapy (≥ 50% reduction in diameter of all disease sites) * No bulky tumor masses, elevated LDH, B symptoms, or progressive disease prior to transplant * Myeloproliferative syndrome with poor risk features, meeting 1 of the following criteria: * \< 55 years old AND Lille score of 1 * Lille score of 2 * HgB \< 10 g/dL AND abnormal karyotype * High-risk disease, with 1 of the following: * Age 40-72 years * Any age AND deemed to be at significantly increased risk of morbidity and death following a standard, myeloablative unrelated donor stem cell transplant (e.g., received extensive prior therapy, including ASCT) * HLA-matched unrelated donor available, with 1 of the following: * 8/8 match at HLA-A, B, C, or DR loci by high-resolution genotyping * Single allelic mismatch at either the HLA-B or HLA-C loci donor by high-resolution molecular typing * No single allelic mismatch at HLA-A or HLA-DR loci * KPS 80-100% * Adapted weighted Charlson Comorbidity Index \< 3 * Serum creatinine ≤ 2.0 mg/dL * AST or ALT \< 3 times upper limit of normal (ULN) * Total bilirubin \< 1.5 times ULN * LVEF ≥ 45% * DLCO \> 50% * No hypoxia at rest with oxygen saturation \< 92% on room air (corrected with bronchodilator therapy) * No other severe pulmonary function abnormalities * No HIV infection * No active hepatitis B or C infection that, in the opinion of a gastroenterologist or the transplant committee, places the patient at moderate to high risk for developing severe hepatic disease * No active opportunistic infection (e.g., fungal pneumonia, tuberculosis, or viral infection)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival at Day 100 | 100 day | Survival at Day 100 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Non-relapse Mortality at Day 100 | Day 100 | patients are evaluable for their cause of death at Day 100 |
| Non-relapse Mortality at 1 Year Post-transplant | 1 year | Number of patients who died of non-relapse causes at one year. this is in clusive of all patients who were transplanted on study even though only 10 patients died at by 1 year time point. This outcome will be referenced in the donor chimerism outcome. Only 26/36 patients were eligible for this time point as that is all that were alive. |
| Complete Donor Chimerism | 2 years | Complete donor chimerism (defined as \>/= 95% donor cells in peripheral blood CD3+ and CD33+ was measured. |
| Neutrophil Recovery | Day 100 | The number of patients experiencing neutrophil recovery post transplant |
| Overall Survival at 1 Year | 1 year | Evaluation of overall survival at 1 year (# of patients who are alive at 1 year post-transplant) |
| Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism | Day 100 | DLI is used for patients with mixed chimerism following transplant |
| Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant | patients were followed for 2 years | patients experiencing acute graft versus host disease post-transplant |
| Number of Patients Experiencing Chronic Graft Versus Host Disease | >100 days post-transplant | — |
| Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant | 4 years | Patients will be evaluated up to 4 years post transplant |
| Platelet Engraftment | Day 100 | The number of patients experiencing platelet engraftment post-transplant |
Countries
United States
Participant flow
Recruitment details
The first patient on this study was enrolled & transplanted on 6/9/05. The last patient on this study was enrolled & transplanted on 1/5/11.
Pre-assignment details
No groups were assigned. Pts received chemotherapy based on their disease. 39 patients consented to study but 36 patients received protocol treatment. 3 patients were considered screen failures and did not move forward on study.
Participants by arm
| Arm | Count |
|---|---|
| Hematopoietic Stem Cell Transplantation All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on disease type | 36 |
| Total | 36 |
Baseline characteristics
| Characteristic | Hematopoietic Stem Cell Transplantation |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 3 Participants |
| Age, Categorical Between 18 and 65 years | 33 Participants |
| Age Continuous | 56.44 years STANDARD_DEVIATION 6.92 |
| Region of Enrollment United States | 36 participants |
| Sex: Female, Male Female | 14 Participants |
| Sex: Female, Male Male | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 36 / 36 |
| serious Total, serious adverse events | 10 / 36 |
Outcome results
Primary
Survival at Day 100
Survival at Day 100
Time frame: 100 day
Population: 36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of overall survival at 100 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Survival at Day 100 | 35 participants |
Secondary
Complete Donor Chimerism
Complete donor chimerism (defined as \>/= 95% donor cells in peripheral blood CD3+ and CD33+ was measured.
Time frame: 2 years
Population: 36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of donor chimerism
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Complete Donor Chimerism | 26 participants |
Secondary
Neutrophil Recovery
The number of patients experiencing neutrophil recovery post transplant
Time frame: Day 100
Population: 36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of neutrophil recovery
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Neutrophil Recovery | 35 participants |
Secondary
Non-relapse Mortality at 1 Year Post-transplant
Number of patients who died of non-relapse causes at one year. this is in clusive of all patients who were transplanted on study even though only 10 patients died at by 1 year time point. This outcome will be referenced in the donor chimerism outcome. Only 26/36 patients were eligible for this time point as that is all that were alive.
Time frame: 1 year
Population: 36 patients underwent hematopoietic stem cell transplant. 10 patients died prior to 1 year post-transplant and were eligible for evaluation of non-relapse mortality at 1 year post-transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Non-relapse Mortality at 1 Year Post-transplant | 4 participants |
Secondary
Non-relapse Mortality at Day 100
patients are evaluable for their cause of death at Day 100
Time frame: Day 100
Population: 36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of non-relapse mortality at Day 100
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Non-relapse Mortality at Day 100 | 1 participants |
Secondary
Number of Patients Experiencing Chronic Graft Versus Host Disease
Time frame: >100 days post-transplant
Population: 35 patients survive past 100 days post-transplant and therefore were eligible for evaluation of chronic graft versus host disease
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Number of Patients Experiencing Chronic Graft Versus Host Disease | 20 participants |
Secondary
Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant
patients experiencing acute graft versus host disease post-transplant
Time frame: patients were followed for 2 years
Population: 36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of acute graft versus host disease post-transplant.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Number of Patients Experiencing Grade 2-4 Acute Graft-versus-host Disease Post-transplant | 15 participants |
Secondary
Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant
Patients will be evaluated up to 4 years post transplant
Time frame: 4 years
Population: 36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of VOD post-transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Number of Patients Experiencing Veno-occlusive Disease (VOD) Post-transplant | 0 participants |
Secondary
Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism
DLI is used for patients with mixed chimerism following transplant
Time frame: Day 100
Population: 36 patients underwent hematopoietic stem cell transplant and therefore were eligible for donor leukocyte infusions for mixed chimerism following transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Number of Patients Requiring the Use of Donor Leukocyte Infusion (DLI) for Early Mixed T-cell Chimerism | 19 participants |
Secondary
Overall Survival at 1 Year
Evaluation of overall survival at 1 year (# of patients who are alive at 1 year post-transplant)
Time frame: 1 year
Population: 36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of overall survival at one year post-transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Overall Survival at 1 Year | 26 participants |
Secondary
Platelet Engraftment
The number of patients experiencing platelet engraftment post-transplant
Time frame: Day 100
Population: 36 patients underwent hematopoietic stem cell transplant and therefore were eligible for evaluation of platelet engraftment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Hematopoietic Stem Cell Transplantation | Platelet Engraftment | 35 participants |